Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*

Wang, Xuan; Wu, Bing; Chen, Ci; Chen, Baihe; Zhang, Wenqing; Xu, Dingli; Bin, Jianping; Liao, Yulin

doi:10.1097/ccm.0b013e31825fd7da

Cited by 52 publications

(51 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, pretreatment of H9c2 cells with resveratrol prior to anoxia/re-oxygenation, reduced cell death in an AMPK and autophagy-dependent manner. Resveratrol was also shown to be protective in cardiomyocytes exposed to anoxia/reoxygenation through inhibition of fractalkine (FKN) [168], which was shown to inhibit the resveratrol-enhancement of autophagy in cardiomyocytes [168]. The roles of FKN and autophagy are important as it has been shown that autophagy is beneficial following MI due to a correction of the myocardial energy imbalance [192].…”

Section: Preclinical Studiesmentioning

confidence: 95%

“…For instance, it has been shown that left ventricular systolic/diastolic function improved and infarct size was reduced in rats that received a daily administration of resveratrol 1 mg/kg for four weeks post-MI [167]. In addition, Xuan et al performed left coronary artery ligation on mice and found that resveratrol (20 mg/kg/day for 42 days) decreased cardiac remodeling and increased survival following the MI [168]. Similar positive results were observed in rats treated with 2.5 mg/kg/day resveratrol for 16 weeks post-MI [169].…”

Section: Preclinical Studiesmentioning

confidence: 96%

“…Resveratrol has been investigated in a number of these models including pressure-overload [208][209][210], volume overload [210], SHRs [30,32], doxorubicin-induced cardiotoxicity [202,203] (see section on chemotherapy-induced cardiotoxicity), MI, ischemia-reperfusion injury [168,169,171], myocarditis [211], and a TO-2 hamster model of heart failure [212] (Table 4). Many studies using resveratrol in these models focus on the ability of resveratrol to prevent cardiac hypertrophy and/or prevent cardiac dysfunction leading to heart failure as opposed to testing resveratrol as a heart failure treatment per se.…”

Section: Preclinical Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Zordoky

Robertson

Dyck

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

278

217

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. Despite advancements in diagnosis and treatment of cardiovascular disease, the incidence of cardiovascular disease is still rising. Therefore, new lines of medications are needed to treat the growing population of patients with cardiovascular disease. Although the majority of the existing pharmacotherapies for cardiovascular disease are synthesized molecules, natural compounds, such as resveratrol, are also being tested. Resveratrol is a non-flavonoid polyphenolic compound, which has several biological effects. Preclinical studies have provided convincing evidence that resveratrol has beneficial effects in animal models of hypertension, atherosclerosis, stroke, ischemic heart disease, arrhythmia, chemotherapy-induced cardiotoxicity, diabetic cardiomyopathy, and heart failure. Although not fully delineated, some of the beneficial cardiovascular effects of resveratrol are mediated through activation of silent information regulator 1 (SIRT1), AMP-activated protein kinase (AMPK), and endogenous anti-oxidant enzymes. In addition to these pathways, the anti-inflammatory, anti-platelet, insulin-sensitizing, and lipid-lowering properties of resveratrol contribute to its beneficial cardiovascular effects. Despite the promise of resveratrol as a treatment for numerous cardiovascular diseases, the clinical studies for resveratrol are still limited. In addition, several conflicting results from trials have been reported, which demonstrates the challenges that face the translation of the exciting preclinical findings to humans. Herein, we will review much of the preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular disease and provide information about the physiological and molecular signaling mechanisms involved. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

show abstract

Section: Preclinical Studiesmentioning

confidence: 95%

Section: Preclinical Studiesmentioning

confidence: 96%

Section: Preclinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Zordoky

Robertson

Dyck

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

278

217

View full text Add to dashboard Cite

show abstract

“…14,15 In rodent models, resveratrol has been shown to prevent and reverse cardiac remodeling. 16,17 It has been demonstrated that tropomyosin mutations are associated with abnormal calcium binding and ventricular remodeling. 18 We noted a significant decrease in tropomyosin 1 (alpha) and tropomyosin 2 (beta) in animals given resveratrol.…”

Section: Discussionmentioning

confidence: 99%

Investigating the Effects of Resveratrol on Chronically Ischemic Myocardium in a Swine Model of Metabolic Syndrome: A Proteomics Analysis

Sabe

Sadek

Elmadhun

et al. 2015

Journal of Medicinal Food

View full text Add to dashboard Cite

Resveratrol has been shown to improve cardiac perfusion and ventricular function after chronic ischemic injury. Using proteomic analysis, we sought to objectively investigate potential mechanisms, by which resveratrol exerts its cardioprotective effects in the setting of metabolic syndrome and chronic myocardial ischemia. Yorkshire swine were divided into two groups based on diet: high cholesterol (n = 7) or a high-cholesterol diet with supplemental resveratrol (n = 6). Four weeks later, all animals underwent surgical placement of an ameroid constrictor to their left circumflex artery. Diets were continued for another 7 weeks, and then the ischemic myocardium was harvested for proteomics analysis. Proteomic analysis identified 669 common proteins between the two groups. Of these proteins, 76 were statistically different, of which 41 were characterized (P < .05). Pathway analysis demonstrated that in animals supplemented with resveratrol, there was a downregulation in several proteins involved with mitochondrial dysfunction, cell death, and unfavorable cardiac remodeling. Furthermore, there was an upregulation in proteins involved in free radical elimination. We conclude that resveratrol supplementation significantly alters several critical protein markers in the chronically ischemic myocardium. Further investigation of these proteins may help elucidate the mechanisms by which resveratrol exerts its cardioprotective effects.

show abstract

“…Inhibition of platelet aggregation and a potential regeneration of tissue in the infarcted area are some RSV effects on myocardial ischemia (Raj et al., 2014). One of protective mechanisms by RSV in cardiomyocytes is induction of autophagy via SIRT‐1 and AMPK activation and inhibition of fractalkine protein as inhibitor of RSV‐induced autophagy (Xuan et al., 2012). Both antioxidant activity and increasing of nitric oxide bioavailability actions of RSV are required to exert its anti‐ischemic effects (Leikert et al., 2002).…”

Section: Resveratrol and Diseasesmentioning

confidence: 99%

Resveratrol: A miraculous natural compound for diseases treatment

Koushki

Amiri-Dashatan

Ahmadi

et al. 2018

Food Science & Nutrition

193

109

View full text Add to dashboard Cite

Resveratrol (3, 5, 4′‐trihydroxystilbene) is a nonflavonoid polyphenol that naturally occurs as phytoalexin. It is produced by plant sources such as grapes, apples, blueberries, plums, and peanut. This compound has critical roles in human health and is well known for its diverse biological activities such as antioxidant and anti‐inflammatory properties. Nowadays, due to rising incidence of different diseases such as cancer and diabetes, efforts to find novel and effective disease‐protective agents have led to the identification of plant‐derived compounds such as resveratrol. Furthermore, several in vitro and in vivo studies have revealed the effectiveness of resveratrol in various diseases such as diabetes mellitus, cardiovascular disease, metabolic syndrome, obesity, inflammatory, neurodegenerative, and age‐related diseases. This review presents an overview of currently available studies on preventive properties and essential molecular mechanisms involved in various diseases.

show abstract

Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*

Abstract: Resveratrol alleviates the deleterious effects of fractalkine on myocardial ischemia and thus reduces subsequent cardiac remodeling.

Cited by 52 publications

References 33 publications

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Investigating the Effects of Resveratrol on Chronically Ischemic Myocardium in a Swine Model of Metabolic Syndrome: A Proteomics Analysis

Resveratrol: A miraculous natural compound for diseases treatment

Contact Info

Product

Resources

About